Ovarian cancer drug study aims to unlock DNA secrets before surgery

NCT ID NCT02659241

First seen Nov 01, 2025 · Last updated Apr 30, 2026 · Updated 22 times

Summary

This early-phase study looks at how the drug adavosertib changes the DNA of advanced ovarian, fallopian tube, or peritoneal cancer in 38 patients before they have surgery. The goal is to understand how the drug affects tumor cells, not to cure or control the disease directly. Results may help doctors plan better treatments in the future.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for FALLOPIAN TUBE HIGH GRADE SEROUS ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • M D Anderson Cancer Center

    Houston, Texas, 77030, United States

  • MD Anderson League City

    League City, Texas, 77573, United States

  • MD Anderson West Houston

    Houston, Texas, 77079, United States

  • MD Anderson in Sugar Land

    Sugar Land, Texas, 77478, United States

  • MD Anderson in The Woodlands

    Conroe, Texas, 77384, United States

  • Memorial Hermann Memorial City Medical Center

    Houston, Texas, 77024, United States

  • OHSU Knight Cancer Institute

    Portland, Oregon, 97239, United States

  • The Woman's Hospital of Texas

    Houston, Texas, 77054, United States

Conditions

Explore the condition pages connected to this study.